title: Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta.
abstract: We examined the in vitro effects of imatinib (Novartis Pharma AG, Basel, Switzerland) as a possible inhibitor of PDGFR pathway on cells derived from a recurrence of a pleural malignant solitary fibrous tumor (SFT). Primary cell culture was characterised by immunofluorescence. SFT-derived cells were treated with imatinib at different time points. Western blotting for PDGFR-beta, phospho-PDGFR-beta or smooth muscle actin (SMA) was performed before and after 96 h of treatment with imatinib. SFT-derived cells treated with imatinib for 96 h showed a dose dependent decrease of Ki67 expression. Results were confirmed by growth curve. Western blotting showed that PDGFR-beta was highly expressed and phosphorylated in SFT-derived cells and imatinib treatment reduced PDGFR-beta phosphorylation and SMA expression. With the limit of experimental findings, our results support a possible future application of imatinib as a candidate molecule in the target therapy of malignant SFTs over-expressing wild-type PDGFR.
authors.affiliation: Department of Biomedical Science and Human Oncology, University of Turin, Italy. marco.prunotto@gmail.com
authors.forename: Marco
authors.initials: M
authors.lastname: Prunotto
authors.forename: Martino
authors.initials: M
authors.lastname: Bosco
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Daniele
authors.forename: Luigia
authors.initials: L
authors.lastname: Macri'
authors.forename: Lisa
authors.initials: L
authors.lastname: Bonello
authors.forename: Laura
authors.initials: L
authors.lastname: Schirosi
authors.forename: Giulio
authors.initials: G
authors.lastname: Rossi
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Filosso
authors.forename: Baudolino
authors.initials: B
authors.lastname: Mussa
authors.forename: Anna
authors.initials: A
authors.lastname: Sapino
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D015153:Blotting, Western; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005455:Fluorescent Antibody Technique; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000068877:Imatinib Mesylate; D066298:In Vitro Techniques; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000473:pathology; D010879:Piperazines / Q000494:pharmacology*; D011013:Pneumonectomy; D011743:Pyrimidines / Q000494:pharmacology*; D011878:Radiotherapy; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000096:biosynthesis; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000096:biosynthesis / Q000187:drug effects*; D054363:Solitary Fibrous Tumor, Pleural / Q000378:metabolism* / Q000473:pathology / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D020796:Receptor, Platelet-Derived Growth Factor alpha; D020797:Receptor, Platelet-Derived Growth Factor beta; D002945:Cisplatin; D005472:Fluorouracil